Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx^®): a placebo-controlled randomised phase II study (PLIANT)

References

• Glimelius B, Cavalli Björkman N. Metastatic colorectal cancer: current treatment and future options for improved survival. Medical approach–present status. Scand J Gastroenterol. 2012;47:296–314.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–2516.
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Lin CS, et al. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol. 2009;27:1243–1249.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Lemmens V, et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol. 2013;31:2699–2707.
   PubMed Web of Science ®Google Scholar
• Wolf SL, Barton DL, Qin R, et al. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer. 2012;20:625–632.
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–437.
   PubMed Web of Science ®Google Scholar
• Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain. 2014;155:2461–2470.
   PubMed Web of Science ®Google Scholar
• Pachman DR, Qin R, Seisler DK, et al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33:3416–3422.
   PubMed Web of Science ®Google Scholar
• Stefansson M, Nygren P. Oxaliplatin added to fluoropyrimidine for adjuvant treatment of colorectal cancer is associated with long-term impairment of peripheral nerve sensory function and quality of life. Acta Oncol. 2016;55:1227–1235.
   PubMed Web of Science ®Google Scholar
• Albers JW, Chaudhry V, Cavaletti G, et al. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev. 2014;3:CD005228.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014;32:1941–1967.
   PubMed Web of Science ®Google Scholar
• Karlsson JO, Kurz T, Flechsig S, et al. Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct. Transl Oncol. 2012;5:492–502.
   PubMed Web of Science ®Google Scholar
• Karlsson JO, Ignarro LJ, Lundstrom I, et al. Calmangafodipir [Ca4Mn(DPDP)5], mangafodipir (MnDPDP) and MnPLED with special reference to their SOD mimetic and therapeutic properties. Drug Discov Today. 2015;20:411–421.
   PubMed Web of Science ®Google Scholar
• Bennett GJ, Doyle T, Salvemini D. Mitotoxicity in distal symmetrical sensory peripheral neuropathies. Nat Rev Neurol. 2014;10:326–336.
   PubMed Web of Science ®Google Scholar
• Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006;122:245–257.
   PubMed Web of Science ®Google Scholar
• Zheng H, Xiao WH, Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. Exp Neurol. 2012;238:225–234.
   PubMed Web of Science ®Google Scholar
• Janes K, Doyle T, Bryant L, et al. Bioenergetic deficits in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide dismutase. Pain. 2013;154:2432–2440.
   PubMed Web of Science ®Google Scholar
• Zheng H, Xiao WH, Bennett GJ. Functional deficits in peripheral nerve mitochondria in rats with paclitaxel- and oxaliplatin-evoked painful peripheral neuropathy. Exp Neurol. 2011;232:154–161.
   PubMed Web of Science ®Google Scholar
• Xiao WH, Bennett GJ. Effects of mitochondrial poisons on the neuropathic pain produced by the chemotherapeutic agents, paclitaxel and oxaliplatin. Pain. 2012;153:704–709.
   PubMed Web of Science ®Google Scholar
• Beckmann H, Kann J, Szadkowski D. The behavior of arterial blood gases and hydrogen-ion concentration under various ventilation conditions. Med Welt. 1966;42:2232–2238.
   PubMedGoogle Scholar
• McCord JM, Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J Biol Chem. 1969;244:6049–6055.
   PubMed Web of Science ®Google Scholar
• Radi R, Cassina A, Hodara R, et al. Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med. 2002;33:1451–1464.
   PubMed Web of Science ®Google Scholar
• Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev. 2007;87:315–424.
   PubMed Web of Science ®Google Scholar
• MacMillan-Crow LA, Crow JP, Kerby JD, et al. Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci USA. 1996;93:11853–11858.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22:229–237.
   PubMed Web of Science ®Google Scholar
• Leonard GD, Wright MA, Quinn MG, et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer. 2005;5:116.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer. 2010;46:479–494.
   PubMed Web of Science ®Google Scholar
• Ventzel L, Madsen CS, Jensen AB, et al. Assessment of acute oxaliplatin-induced cold allodynia: a pilot study. Acta Neurol Scand. 2016;133:152–155.
   PubMed Web of Science ®Google Scholar
• Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol. 2011;29:421–427.
   PubMed Web of Science ®Google Scholar
• Cassidy J, Bjarnason GA, Hickish T, et al. Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC). J Clin Oncol. 2006;24:3507.
   Google Scholar
• Durand JP, Deplanque G, Montheil V, et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23:200–205.
   PubMed Web of Science ®Google Scholar
• Cascinu S, Catalano V, Cordella L, et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2002;20:3478–3483.
   PubMed Web of Science ®Google Scholar
• Wang WS, Lin JK, Lin TC, et al. Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist. 2007;12:312–319.
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Welshman EE, Chang CH, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer. 2003;13:741–748.
   PubMed Web of Science ®Google Scholar
• Postma TJ, Aaronson NK, Heimans JJ, et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer. 2005;41:1135–1139.
   PubMed Web of Science ®Google Scholar
• Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol. 2014;32:997–1005.
   PubMed Web of Science ®Google Scholar
• Iveson T, Kerr R, Saunders MP, et al. Toxicity and quality of life data from SCOT: an international phase III randomized (1:1) noninferiority trial comparing 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy. J Clin Oncol. 2015;33:suppl:abstr 3514.
   Web of Science ®Google Scholar
• Cleeland CS, Farrar JT, Hausheer FH. Assessment of cancer-related neuropathy and neuropathic pain. Oncologist. 2010;15 Suppl 2:13–18.
   PubMed Web of Science ®Google Scholar
• Postma TJ, Heimans JJ, Muller MJ, et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol. 1998;9:739–744.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Till C, Wright JD, et al. Comorbidities and risk of chemotherapy-induced peripheral neuropathy among participants 65 years or older in southwest oncology group clinical trials. J Clin Oncol. 2016;34:3014–3022.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Yothers G, O'Connell MJ, et al. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J Clin Oncol. 2009;27:3385–3390.
   PubMed Web of Science ®Google Scholar
• Alexandre J, Nicco C, Chereau C, et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst. 2006;98:236–244.
   PubMed Web of Science ®Google Scholar
• Kurz T, Grant D, Andersson RG, et al. Effects of MnDPDP and ICRF-187 on doxorubicin-induced cardiotoxicity and anticancer activity. Transl Oncol. 2012;5:252–259.
   PubMed Web of Science ®Google Scholar
• Laurent A, Nicco C, Chereau C, et al. Controlling tumour growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65:948–956.
   PubMed Web of Science ®Google Scholar
• Rocklage SM, Cacheris WP, Quay SC, et al. Manganese(II) N,N’-dipyridoxylethylenediamine-N,N’-diacetate5, 5’-Bis (phosphate). Synthesis and characterization of a paramagnetic chelate for magnetic resonance imaging enhancement. Inorg Chem. 1989;28:477–485.
   Web of Science ®Google Scholar
• Schmidt PP, Toft KG, Skotland T, et al. Stability and transmetallation of the magnetic resonance contrast agent MnDPDP measured by EPR. J Biol Inorg Chem. 2002;7:241–248.
   PubMed Web of Science ®Google Scholar
• Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13:342–355.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Senovilla L, et al. Immunogenic tumour cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010;16:3100–3104.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–1422.
   PubMed Web of Science ®Google Scholar